Dr. Corina Shtir is Senior Director of Translational Medicine at Thermo Fisher Scientific. She joined the company in 2013, from the Wellcome Trust Diabetes and Inflammatory Lab (DIL) in Cambridge, UK. Her expertise spans many areas, enabling her to take an integrative approach to driving population-scale programs for both rare and complex disorders. Her specialties include population genetics and biostatistics (PhD), statistical genetics, mathematics, epidemiology, and computational biology. Her research collaborators in these areas include world-renowned scientists. She directs programs such as the Saudi Human Genome Program, Stratified Medicine Scotland, the Taiwan National Genome Program, and other mid-East and European large-scale efforts. Dr. Shtir serves as a scientific advisor on many committees and initiatives, including the US Million Veteran Program, the largest US government program aimed at correlating genome sequences with health care information for use in personalized medicine.
Prior to joining Thermo Fisher, Corina worked with John Todd, director of the Wellcome Trust DIL, and with David Clayton, previously head of Statistical Genetics at Cambridge Institute of Medical Research (CIMR), UK. While at the DIL, she developed a comprehensive method for detection and correction of artifacts in estimation of rare copy number variants and analysis of rare deletions in type 1 diabetes, a collaborative work between the Wellcome Trust, CIMR, and the University of Virginia. In the UK, she also collaborated with Kings College leaders on studying autoimmune disorders. Corina also collaborated and published with scientific specialists in neurodevelopmental disorders (UCLA, USC, University of Pennsylvania, Cardiff Centre for Neuropsychiatric Genomics, UK), and in age-related macular degeneration and other complex disorders.